Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data
2011

Study of Bupropion for African American Light Smokers

Sample size: 540 publication 10 minutes Evidence: moderate

Author Information

Author(s): Lisa Sanderson Cox, Babalola Faseru, Matthew S Mayo, Ron Krebill, Tricia S Snow, Carrie A Bronars, Nicole L Nollen, Wonsuk Choi, Kolawole S Okuyemi, Gary A Salzman, Neal L Benowitz, Rachel F Tyndale, Jasjit S Ahluwalia

Primary Institution: University of Kansas Medical Center

Hypothesis

Can bupropion effectively aid smoking cessation in African American light smokers?

Conclusion

The study demonstrated the feasibility of recruiting African American light smokers for a clinical trial involving genetic analysis and showed high motivation among participants to quit smoking.

Supporting Evidence

  • Participants had a mean age of 46.5 years and 66.1% were women.
  • Participants smoked an average of 8.0 cigarettes per day.
  • 72.2% of participants smoked within 30 minutes of waking.

Takeaway

This study looked at how a medicine called bupropion can help African American light smokers stop smoking. It found that many people wanted to quit and were willing to participate in the study.

Methodology

Participants were randomly assigned to receive either bupropion or a placebo for 7 weeks, along with health education counseling.

Limitations

The study primarily included low-income African American light smokers, which may limit generalizability to other populations.

Participant Demographics

{"mean_age":46.5,"percentage_women":66.1,"percentage_smoking_menthol":83.7,"percentage_low_income":60.7}

Digital Object Identifier (DOI)

10.1186/1745-6215-12-22

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication